SI2934510T1 - Formulacije zaviralca LFA-1 - Google Patents

Formulacije zaviralca LFA-1

Info

Publication number
SI2934510T1
SI2934510T1 SI201331833T SI201331833T SI2934510T1 SI 2934510 T1 SI2934510 T1 SI 2934510T1 SI 201331833 T SI201331833 T SI 201331833T SI 201331833 T SI201331833 T SI 201331833T SI 2934510 T1 SI2934510 T1 SI 2934510T1
Authority
SI
Slovenia
Prior art keywords
lfa
inhibitor formulations
formulations
inhibitor
Prior art date
Application number
SI201331833T
Other languages
English (en)
Slovenian (sl)
Inventor
Mary Newman
William Hunke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2934510(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2934510T1 publication Critical patent/SI2934510T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI201331833T 2012-12-19 2013-12-18 Formulacije zaviralca LFA-1 SI2934510T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29
PCT/US2013/076041 WO2014100135A1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations
EP13865757.2A EP2934510B1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations

Publications (1)

Publication Number Publication Date
SI2934510T1 true SI2934510T1 (sl) 2021-02-26

Family

ID=50979140

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331833T SI2934510T1 (sl) 2012-12-19 2013-12-18 Formulacije zaviralca LFA-1

Country Status (20)

Country Link
US (2) US11058677B2 (OSRAM)
EP (2) EP3827823A1 (OSRAM)
JP (1) JP6373867B2 (OSRAM)
KR (1) KR101891144B1 (OSRAM)
CN (1) CN104955453B (OSRAM)
AU (1) AU2013361579B2 (OSRAM)
BR (1) BR112015014367B1 (OSRAM)
CA (1) CA2894170C (OSRAM)
DK (1) DK2934510T3 (OSRAM)
EA (2) EA201791321A1 (OSRAM)
ES (1) ES2846724T3 (OSRAM)
HU (1) HUE052299T2 (OSRAM)
IL (1) IL239490B (OSRAM)
MX (2) MX391620B (OSRAM)
NZ (1) NZ708821A (OSRAM)
PL (1) PL2934510T3 (OSRAM)
PT (1) PT2934510T (OSRAM)
SI (1) SI2934510T1 (OSRAM)
WO (1) WO2014100135A1 (OSRAM)
ZA (2) ZA201504404B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
JP7700045B2 (ja) * 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
US20230399317A1 (en) * 2020-10-21 2023-12-14 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
WO2025104294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Semifluorinated alkane small molecule lfa-1 antagonist combination compositions for treatment of ocular disorders
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
DK0642332T3 (da) * 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) * 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
ES2530780T3 (es) * 2005-05-17 2015-03-05 Sarcode Bioscience Inc Composiciones y métodos para el tratamiento de trastornos oculares
ES2437077T3 (es) * 2005-07-08 2014-01-08 Senju Pharmaceutical Co., Ltd. Preparado oftálmico de absorción percutánea que comprende olopatadina
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011521896A (ja) 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
US20120028929A1 (en) * 2008-09-19 2012-02-02 Alacrity Bioscience, Inc. Tetracycline stabilizing formulations
CN102176920B (zh) * 2008-11-17 2013-09-18 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
JP5659388B2 (ja) * 2009-06-10 2015-01-28 マイトテック ソシエテ アノニム 医学及び獣医眼科の使用のための医薬組成物
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
CN104367580A (zh) * 2009-11-23 2015-02-25 阿勒根公司 晶型ii的7-[3,5-二羟基-2-(3-羟基-5-苯基-戊-1-烯基)-环戊基]-n-乙基-庚-5-烯酰胺(比马前列素)、其制备方法和使用方法
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
US20130317058A1 (en) * 2011-02-18 2013-11-28 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
JP2014518278A (ja) * 2011-06-29 2014-07-28 アラーガン インコーポレイテッド 蕁麻疹の治療に用いるアルカフタジン
ES2978927T3 (es) * 2012-03-29 2024-09-23 Epion Therapeutics Inc Soluciones de tratamiento ocular, dispositivos de administración y métodos de aumento de la administración
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
CA2894170C (en) 2021-08-10
KR20150100763A (ko) 2015-09-02
AU2013361579B2 (en) 2018-05-24
BR112015014367A2 (pt) 2017-07-11
US20220000859A1 (en) 2022-01-06
WO2014100135A1 (en) 2014-06-26
CN104955453A (zh) 2015-09-30
NZ708821A (en) 2020-03-27
AU2013361579A1 (en) 2015-06-18
IL239490A0 (en) 2015-08-31
KR101891144B1 (ko) 2018-08-23
US11058677B2 (en) 2021-07-13
JP6373867B2 (ja) 2018-08-15
EP3827823A1 (en) 2021-06-02
EA201791321A1 (ru) 2018-04-30
EP2934510A1 (en) 2015-10-28
PT2934510T (pt) 2021-01-13
US20150320737A1 (en) 2015-11-12
EP2934510A4 (en) 2016-08-17
HK1214536A1 (zh) 2016-07-29
MX368876B (es) 2019-10-21
ZA201504404B (en) 2020-01-29
MX2019012375A (es) 2020-01-20
PL2934510T3 (pl) 2021-07-05
HUE052299T2 (hu) 2021-04-28
IL239490B (en) 2018-12-31
BR112015014367B1 (pt) 2022-11-22
HK1214963A1 (en) 2016-08-12
JP2016503058A (ja) 2016-02-01
CA2894170A1 (en) 2014-06-26
MX391620B (es) 2025-03-19
EP2934510B1 (en) 2020-10-28
EA028008B1 (ru) 2017-09-29
MX2015007540A (es) 2016-04-13
DK2934510T3 (da) 2021-01-25
ES2846724T3 (es) 2021-07-29
ZA201608069B (en) 2017-11-29
EA201591180A1 (ru) 2015-12-30
CN104955453B (zh) 2018-09-18

Similar Documents

Publication Publication Date Title
SMT201700596T1 (it) Composti inibitori
GB2524921B (en) Pusher
ZA201608069B (en) Lfa-1 inhibitor formulations
PT2804611T (pt) Composições derivadas da quitosana
GB201322986D0 (en) Compositions
IL235919A0 (en) inhibitors of fbxo3
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
GB201201287D0 (en) Compositions
GB201211019D0 (en) Inhibitor compounds
GB201220068D0 (en) Compositions
GB201318407D0 (en) Compositions
GB201219980D0 (en) Compositions
GB201219973D0 (en) Compositions
GB201219962D0 (en) Compositions
GB201206178D0 (en) Formulations
GB201216524D0 (en) Project P
GB201200323D0 (en) Easihang 45?/90?
GB201220595D0 (en) Keysafe application
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201213825D0 (en) Damper-device for bouncing-device
GB201211247D0 (en) Improved formulation
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions
GB201210424D0 (en) Poop - pole N?2